Mankind Pharma shares show resilience, with analyst eyeing improved margins
JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 ...
devdiscourse7d
Mankind Pharma's Revenue Growth Defies Profit Decline
Mankind Pharma reported a 16.5% decrease in consolidated net profit for Q3 2024, despite a 24% increase in revenue. The company has recently acquired Bharat Serums and Vaccines, which contributed to ...